Claritev Net Income From Continuing Ops Over Time
| CTEV Stock | 19.98 0.82 3.94% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Claritev Performance and Claritev Correlation. What growth prospects exist in Health Care Equipment & Supplies sector? Can Claritev capture new markets? Factors like these will boost the valuation of Claritev. Projected growth potential of Claritev fundamentally drives upward valuation adjustments. Valuation analysis balances hard financial data with qualitative growth assessments. While each Claritev valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Earnings Share (20.91) | Revenue Per Share | Quarterly Revenue Growth 0.067 | Return On Assets | Return On Equity |
Investors evaluate Claritev using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Claritev's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. External factors like market trends, sector rotation, and investor psychology can cause Claritev's market price to deviate significantly from intrinsic value.
It's important to distinguish between Claritev's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Claritev should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Claritev's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Claritev and related stocks such as Goodrx Holdings, Opko Health, and Evolent Health Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GDRX | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 66 M | (293.6 M) | (25.3 M) | (32.8 M) | 15 M | 16.4 M | 18.8 M | 19.8 M |
| OPK | (4.9 M) | (4.9 M) | (27.6 M) | (117.3 M) | (171.1 M) | (31.4 M) | (17.4 M) | (294.4 M) | (138.5 M) | (312 M) | 31.1 M | (30.1 M) | (328.4 M) | (207.6 M) | (53.2 M) | (47.9 M) | (50.3 M) |
| EVH | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | 319.8 M | (226.8 M) | (69.8 M) | (52.7 M) | (302 M) | (334.2 M) | (30.3 M) | (18.7 M) | (113 M) | (61.6 M) | (55.5 M) | (58.2 M) |
| IART | 65.7 M | 28 M | 41.2 M | (17 M) | 34 M | 6.9 M | 74.6 M | 64.7 M | 60.8 M | 50.2 M | 133.9 M | 169.1 M | 180.6 M | 67.7 M | (6.9 M) | (8 M) | (7.6 M) |
| SANA | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (285.3 M) | (355.9 M) | (269.5 M) | (283.3 M) | (266.8 M) | (240.1 M) | (252.1 M) |
| IRMD | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 7.5 M | 7.2 M | 499.8 K | 6.3 M | 9.6 M | 1.4 M | 9.3 M | 12.8 M | 16.3 M | 19.2 M | 22.1 M | 23.2 M |
| AXGN | (9.2 M) | (9.2 M) | (10.9 M) | (14.6 M) | (17.7 M) | (13.4 M) | (14.4 M) | (10.4 M) | (22.4 M) | (29.1 M) | (23.8 M) | (27 M) | (28.9 M) | (23.2 M) | (10 M) | (9 M) | (9.4 M) |
| INMD | 336 K | 336 K | 336 K | 336 K | 336 K | 336 K | 336 K | 8.8 M | 22.4 M | 61.2 M | 75 M | 165.1 M | 161.5 M | 197.9 M | 181.3 M | 93.8 M | 106.4 M |
| LFMD | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.4 M) | (3.5 M) | (60.5 M) | (61.3 M) | (45 M) | (26.2 M) | (18.7 M) | (16.9 M) | (17.7 M) |
| DNTH | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (28.5 M) | (43.1 M) | (85 M) | (76.5 M) | (72.6 M) |
Claritev and related stocks such as Goodrx Holdings, Opko Health, and Evolent Health Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Claritev | CTEV |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 7900 Tysons One |
| Exchange | New York Stock Exchange |
null 19.98
Additional Tools for Claritev Stock Analysis
When running Claritev's price analysis, check to measure Claritev's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Claritev is operating at the current time. Most of Claritev's value examination focuses on studying past and present price action to predict the probability of Claritev's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Claritev's price. Additionally, you may evaluate how the addition of Claritev to your portfolios can decrease your overall portfolio volatility.